4569 KYORIN Pharmaceutical Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4569

TSE Prime

KYORIN Pharmaceutical Co.,Ltd.

1,453

JPY

(+0.41%)

Dec 23, 3:30 pm JST

9.27

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	102,904	5,786	6,447	6,130	107.0	75	May 11, 2021	J-GAAP
Mar, 2022	105,534	5,007	5,569	3,932	68.6	52	May 11, 2022	J-GAAP
Mar, 2023	113,270	5,123	5,827	4,723	82.4	52	May 11, 2023	J-GAAP
Mar, 2024	119,532	6,013	6,602	5,322	92.7	52	May 10, 2024	J-GAAP
Mar, 2025 Guidance	123,400	6,500	6,900	5,000	87.0	52	May 10, 2024	J-GAAP
YoY	+3.2%	+8.1%	+4.5%	-6.1%	-6.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 13, 2019	114,100	9,100	9,600	7,100	75	J-GAAP
	Nov 7, 2019	109,400	6,500	7,100	5,400	75	J-GAAP
Results	May 12, 2020	109,983	7,503	8,175	6,149	75	J-GAAP
Mar, 2021	May 12, 2020	Available in future release
	Nov 5, 2020
	May 7, 2021
Results	May 11, 2021
Mar, 2022	May 11, 2021
	Apr 26, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
Results	May 11, 2023
Mar, 2024	May 11, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024	123,400	6,500	6,900	5,000	52	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	52,776	+12.5	Available in future release
Mar, 2001	55,832	+5.8
Mar, 2002	62,395	+11.8
Mar, 2003	68,618	+10.0
Mar, 2004	65,061	-5.2
Mar, 2005	66,296	+1.9
Mar, 2006	74,054	+11.7
Mar, 2007	77,093	+4.1
Mar, 2008	81,070	+5.2
Mar, 2009	90,889	+12.1
Mar, 2010	99,764	+9.8
Mar, 2011	104,069	+4.3
Mar, 2012	103,232	-0.8
Mar, 2013	107,031	+3.7
Mar, 2014	111,400	+4.1
Mar, 2015	113,121	+1.5
Mar, 2016	119,483	+5.6
Mar, 2017	115,373	-3.4
Mar, 2018	110,640	-4.1
Mar, 2019	113,620	+2.7
Mar, 2020	109,983	-3.2
Mar, 2021	102,904	-6.4
Mar, 2022	105,534	+2.6
Mar, 2023	113,270	+7.3
Mar, 2024	119,532	+5.5
Mar, 2025 Guidance	123,400	+3.2	6,500	+8.1	6,900	+4.5	87.0	-6.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	113,270	5,123	4.52	3.78	2.71	0.65	82.4
Mar, 2024	119,532	6,013	5.03	4.15	3.01	0.68	92.7
Mar, 2025 Guidance	123,400	6,500	5.27	3.85	2.80	0.69	87.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	119,532	19,636	19,995	13,639	184.3
Fiscal Year	Mar, 2024	Mar, 2016	Mar, 2016	Mar, 2016	Mar, 2016

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	56,432	5,075	5,284	3,811	66.5	32	May 11, 2022	J-GAAP
Oct - Mar, 2022	64,177	4,346	4,656	3,481	60.8	32	May 11, 2023	J-GAAP
Oct - Mar, 2023	64,595	4,678	5,024	3,432	59.8	32	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	68,261	4,951	4,850	3,745	65.2	32	Nov 7, 2024	J-GAAP
YoY	+5.7%	+5.8%	-3.5%	+9.1%	+9.0%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	5,007	3,786	6,346	-2,560	-4,112	26,289	15.29	J-GAAP
Mar, 2023	5,123	-4,267	2,008	-6,275	-3,363	18,816	10.69	J-GAAP
Mar, 2024	6,013	-1,638	1,549	-3,187	-3,347	13,886	7.82	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	49,093	777	1,171	1,242	21.7	20.1	Nov 9, 2022	J-GAAP
Apr - Sep, 2023	54,937	1,335	1,578	1,890	33.0	23.9	Nov 8, 2023	J-GAAP
Apr - Sep, 2024	55,139	1,549	2,050	1,255	21.9	29.7	Nov 7, 2024	J-GAAP
YoY	+0.4%	+16.0%	+29.9%	-33.6%	-33.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	31,614	3,925	4,165	3,135	54.7	12.4	Feb 6, 2023	J-GAAP
Jan - Mar, 2023	32,563	421	491	346	6.0	1.3	May 11, 2023	J-GAAP
Apr - Jun, 2023	27,854	871	1,074	787	13.8	3.1	Aug 2, 2023	J-GAAP
Jul - Sep, 2023	27,083	464	504	1,103	19.2	1.7	Nov 8, 2023	J-GAAP
Oct - Dec, 2023	32,330	3,130	3,475	2,024	35.3	9.7	Feb 6, 2024	J-GAAP
Jan - Mar, 2024	32,265	1,548	1,549	1,408	24.5	4.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	28,419	1,150	1,417	885	15.4	4.0	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	26,720	399	633	370	6.4	1.5	Nov 7, 2024	J-GAAP
YoY	-1.3%	-14.0%	+25.6%	-66.5%	-66.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	30,315	-4.2	Available in future release
Jan - Mar, 2020	31,369	-0.7
Apr - Jun, 2020	24,689	-4.1
Jul - Sep, 2020	23,046	+2.2
Oct - Dec, 2020	27,220	-10.2
Jan - Mar, 2021	27,949	-10.9
Apr - Jun, 2021	24,695	0.0
Jul - Sep, 2021	24,407	+5.9
Oct - Dec, 2021	28,615	+5.1
Jan - Mar, 2022	27,817	-0.5
Apr - Jun, 2022	24,619	-0.3
Jul - Sep, 2022	24,474	+0.3
Oct - Dec, 2022	31,614	+10.5
Jan - Mar, 2023	32,563	+17.1
Apr - Jun, 2023	27,854	+13.1
Jul - Sep, 2023	27,083	+10.7
Oct - Dec, 2023	32,330	+2.3
Jan - Mar, 2024	32,265	-0.9
Apr - Jun, 2024	28,419	+2.0
Jul - Sep, 2024	26,720	-1.3	399	-14.0	633	+25.6	6.4	-66.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	37,083	10,567	10,680	7,864	106.2
Fiscal Year	Dec, 2015	Dec, 2015	Dec, 2015	Dec, 2015	Dec, 2015

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	2,172.83	72.4	171,924	124,507	132,710	0.17	May 11, 2022	J-GAAP
Mar, 2023	2,189.40	71.3	176,045	125,461	134,396	0.17	May 11, 2023	J-GAAP
Mar, 2024	2,276.52	73.6	177,627	130,735	136,726	0.16	May 10, 2024	J-GAAP
Apr - Sep, 2024	ー	72.7	178,865	130,027	136,121	0.19	Nov 7, 2024	J-GAAP

KYORIN Pharmaceutical Co.,Ltd.(4569) Financial Results